SCHEMBL951055

SCHEMBL951055

CSCCc1ccccn1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.55
HRH3 Q9Y5N1 2/20 0.55
ALDH1A1 P00352 3/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
LMNA P02545 2/20 0.53
TAAR1 Q96RJ0 1/20 0.53
ALOX15 P16050 1/20 0.53
CYP1A2 P05177 3/20 0.47
CYP2C19 P33261 1/20 0.47
HRH4 Q9H3N8 1/20 0.47
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27679728 0.98 HRH1 (0.53) HRH1HRH3ALDH1A1NPC1RAB9A
Oxalic Acid SCHEMBL28775065 0.89 CYP1A2 (0.50) HRH1HRH3ALDH1A1NPC1RAB9A
SCHEMBL28723685 0.89 HTT (0.51) HRH1HRH3ALDH1A1NPC1RAB9A
SCHEMBL949945 0.88 HRH1 (0.55) HRH1HRH3ALDH1A1NPC1RAB9A
Oxalic Acid SCHEMBL1156072 0.88 HTT (0.49) HRH1HRH3ALDH1A1NPC1RAB9A
SCHEMBL11464130 0.83 HRH1 (0.59) HRH1HRH3ALDH1A1NPC1RAB9A
SCHEMBL29595035 0.81 HTT (0.58) HRH1HRH3ALDH1A1NPC1RAB9A
SCHEMBL1825837 0.81 HTT (0.58) HRH1HRH3ALDH1A1NPC1RAB9A
SCHEMBL5941270 0.80 ALDH1A1 (0.59) HRH1HRH3ALDH1A1NPC1RAB9A
SCHEMBL8280335 0.80 HRH1 (0.52) HRH1HRH3ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7888523-B2 Preparation of platinum(II) complexes PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2011-02-15 US claimed
US-7589225-B2 Preparation of platinum(II) complexes PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2009-09-15 US claimed
US-7576126-B2 Platinum (II) complexes, preparation and use PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2009-08-18 US claimed
EP-1789427-B1 PREPARATION OF PLATINUM(II) COMPLEXES PLATCO TECHNOLOGIES PROPRIETAR (ZA) 2009-05-20 EP claimed
US-20080064895-A1 Preparation of Platinum(II) Complexes PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2008-03-13 US claimed
CN-101018797-A Preparation of platinum (II) complexes PLATCO TECHNOLOGIES PROPRIETAR (ZA) 2007-08-15 CN claimed
US-20070167643-A1 Platinum (II) complexes, preparation and use PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2007-07-19 US claimed
EP-1789427-A1 PREPARATION OF PLATINUM(II) COMPLEXES Platco Technologies (Proprietary) Limited (ZA) 2007-05-30 EP claimed
EP-1704156-A1 PLATINUM(II) COMPLEXES, PREPARATION AND USE Platco Technologies (Proprietary) Limited (ZA) 2006-09-27 EP claimed
WO-2006024897-A1 PREPARATION OF PLATINUM(II) COMPLEXES PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2006-03-09 WO claimed
WO-2005051966-A1 PLATINUM(II) COMPLEXES, PREPARATION AND USE PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2005-06-09 WO claimed
US-4038435-A FLAVORING AGENT FIRMENICH & CIE (CH) 1977-07-26 US claimed
US-9895443-B2 Multi-tailed lipids and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-02-20 US disclosed
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 WO disclosed
US-8329704-B2 Substituted pyrazinone derivatives for use in MCH-1 mediated diseases JANSSEN PHARMACEUTICA, N.V. (BE) 2012-12-11 US disclosed
US-8329704-B2 Substituted pyrazinone derivatives for use in MCH-1 mediated diseases JANSSEN PHARMACEUTICA, N.V. (BE) 2012-12-11 US disclosed
US-3952026-A FLAVOR ADDITIVE FOR FOODS AND BEVERAGES FIRMENICH & CIE (CH) 1976-04-20 US disclosed
US-3943260-A TETRAHYDRO-THIO-PHEN-3-ONES FIRMENICH & CIE (CH) 1976-03-09 US disclosed
US-3931245-A FURYLALKYLTHIOL CARBOXYLATES FIRMENICH & CIE (CH) 1976-01-06 US disclosed
US-3931246-A FURYLALKYL-THIOETHERS FIRMENICH & CIE (CH) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167643-A1 Platinum (II) complexes, preparation and use PDCD5, ORC3, PDCD2L HRH1 3638/4885HRH3 2178/4885ALDH1A1 3930/4885
US-20080064895-A1 Preparation of Platinum(II) Complexes SLCO4C1, SLC10A6, OTC HRH1 3361/4885HRH3 2231/4885ALDH1A1 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.